標普和納斯達克內在價值 聯繫我們
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← 返回所有股票

Danaher Corporation DHR-PB NYSE

NYSE • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
62/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Danaher Corporation (DHR-PB) 是一家 Medical - Diagnostics & Research 公司，屬於 醫療保健 產業, 目前交易價格為 $1,261.26. 其SharesGrow評分為 62/100, 表明 高於平均 的投資特徵， 7項中通過3項.

財務數據: 營收為 $24.6B, -7.1%/yr 平均成長. 淨利潤為 $3.6B, 成長率為 -19.8%/yr. 淨利潤率為 14.7% (健康). 毛利率為 60.9% (+0.7 pp 趨勢).

資產負債表: 總債務為 $18.4B 對比 $52.5B 股東權益 (D/E比率 0.35, 保守). 流動比率為 1.87 (流動性強). 資產負債率為 22.1%. 總資產: $83.5B.

分析師展望: 5 / 8 位分析師評級 DHR-PB 為買入 (63%) — 適度共識.

SharesGrow 7項標準細分: Value 15/100 (Fail), Growth 15/100 (Fail), Past 100/100 (Pass), Health 100/100 (Pass), Moat 92/100 (Pass), Future 55/100 (Partial), Income 55/100 (Partial).

DHR-PB SharesGrow 評分概覽

62/100
SharesGrow Score
Above average fundamentals
View full scorecard →
價值 15/100
估值 — P/E, PEG, Forward PEG
成長 15/100
財務數據 — 平均成長
過去 100/100
強勁 — 趨勢
健康 100/100
資產負債表 — D/E比率, 流動比率為
護城河 92/100
毛利率為 + market cap
未來 55/100
分析師展望 — 為買入
收入 55/100
淨利潤率為
Scores derived from financial statements, analyst ratings, and balance sheet data.

評分明細 — DHR-PB

✗
價值 Fail
15/100
DHR-PB 本益比(P/E)為 N/A (S&P 500平均約25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + 上漲空間 (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
成長 Fail
15/100
DHR-PB: -7.1%/yr 營收為, -19.8%/yr 淨利潤為 平均成長. 較弱. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✓
過去 Pass
100/100
DHR-PB: 4 / 4 年獲利. 強勁 — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.
View details →
✓
健康 Pass
100/100
資產負債表 DHR-PB: D/E比率 0.35 (保守), 流動比率為 1.87 (流動性強). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
護城河 Pass
92/100
DHR-PB: 毛利率為 60.9% (+0.7 pp 趨勢), $917B market cap. Moat (0-100): margin (35%) + 趨勢 (15%) + market cap (30%) + 營收為 (20%). Score 92/100. ≥ 70 = Pass.
View details →
~
未來 Partial
55/100
分析師展望: 5 / 8 位分析師評級 DHR-PB 為買入 (63%). Score: 60% buy consensus + 40% 上漲空間. ≥ 60 = Pass.
View details →
~
收入 Partial
55/100
DHR-PB: 淨利潤率為 14.7%. 較薄 (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

市場數據
52週區間1199.99-1521.85
成交量152.33K
30日平均成交量12.97K
市值$916.76B
Beta（1年）0.80
股息率$50.0000
Share Statistics
EPS（TTM）5.07
流通股數$707.3M
IPO Date2020-05-11
Employees79,000
CEORainer M. Blair
Financial Highlights & Ratios
Revenue (TTM)$24.57B
Gross Profit$14.97B
EBITDA$6.95B
Net Income$3.61B
Operating Income$5.14B
Total Cash$4.62B
Total Debt$18.42B
Net Debt$13.8B
Total Assets$83.46B
Price / Earnings (P/E)248.8
Price / Sales (P/S)37.32
Analyst Forecast
評級共識Buy
覆蓋分析師數8
買入 63% 持有 38% 賣出 0%
公司資訊
國家US
交易所NYSE
貨幣USD
ISINUS2358514097

股價走勢

Track all markets on TradingView
DHR-PB
Danaher Corporation ↗  ·  NYSE
Healthcare • Medical - Diagnostics & Research
1,199.99 52WK RANGE 1,521.85

其他人也在看

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
聯繫我們
🎓
SharesGrow 學院
學習如何計算內在價值，發現被低估的股票。
每週線上課程
📧 [email protected]
📞 +65 8912 8000
給我們留言